Identification

Name
Olaparib
Accession Number
DB09074  (DB05940)
Type
Small Molecule
Groups
Approved
Description

Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

Olaparib is available as oral tablets marketed under the brand name Lynparza and was initially indicated as a maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. On January 12, 2018, FDA expanded the approved use of Lynparza to include chemotherapy-experienced patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In a randomized clinical trial involving patients with HER2-negative metastatic breast cancer with a germline BRCA mutation, the median progression-free survival for patients taking Lynparza was 7 months compared to 4.2 months for patients taking chemotherapy only. Patient selection for this newly-approved indication can be performed based on an FDA-approved genetic test, called the BRACAnalysis CDx.

Structure
Thumb
Synonyms
  • 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
External IDs
AZD 2281 / AZD-2281 / AZD2281 / KU-0059436 / KU-59436 / KU59436
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LynparzaCapsule50 mgOralAstra Zeneca2016-05-16Not applicableCanada
LynparzaTablet, film coated100 mg/1OralAstra Zeneca Lp2017-08-17Not applicableUs
LynparzaCapsule50 mg/1OralAstra Zeneca Lp2014-12-23Not applicableUs
LynparzaTablet, film coated150 mg/1OralAstra Zeneca Lp2017-08-17Not applicableUs
Categories
UNII
WOH1JD9AR8
CAS number
763113-22-0
Weight
Average: 434.4628
Monoisotopic: 434.175418827
Chemical Formula
C24H23FN4O3
InChI Key
FDLYAMZZIXQODN-UHFFFAOYSA-N
InChI
InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
IUPAC Name
4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}phthalazin-1-ol
SMILES
OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12

Pharmacology

Indication
  • Indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

  • Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

  • Indicated for the treatment of patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, who have been previously treated with chemotherapy.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

TargetActionsOrganism
APoly [ADP-ribose] polymerase 1
inhibitor
Human
APoly [ADP-ribose] polymerase 2
inhibitor
Human
APoly [ADP-ribose] polymerase 3
inhibitor
Human
Absorption

Peak plasma concentrations achieved typically between 1 to 3 hours following oral administration of olaparib in capsule formulation.

Volume of distribution

167 +/-196 L following a single dose of 400mg olaparib.

Protein binding

Approximately 82%.

Metabolism

Primarily CYP3A4 in vitro.

Route of elimination

44% via the urine and 42% via the feces.

Half life

11.9 hours, standard deviation 4.8 hours.

Clearance

8.6 +/- 7.1L/h.

Toxicity

The most commonly reported side effects reported during clinical trials included cough, constipation, dysguesia, peripheral deem, back pain, dizziness, headache, urinary tract infection, dyspnea, and rash. Myelodysplastic syndrome/Acute Myeloid Leukemia (MDS/AML) was reported in 2% of patients with deleterious or suspected deleterious germline BRCA-mutated advanced cancers. The majority of cases were fatal and the duration of therapy with olaparib in patients who developed secondary cancers varied from <6 months to >2 years. Complete blood count should be tested at baseline and monthly following therapy initiation to monitor for MDS/AML. Pneumonitis, including fatal cases, occurred in <1% of patients treated with olaparib. Patients should be monitored for new or worsening respiratory symptoms such as dyspnea, fever, cough, or wheezing. Olaparib was found to be teratogenic and causes embryo-fetal toxicity in rats. It should therefore be avoided during pregnancy and its use should be a combined with an effective contraception during treatment.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Olaparib.Approved, Investigational
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Olaparib.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Olaparib.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Olaparib.Approved
Acetyl sulfisoxazoleThe serum concentration of Olaparib can be increased when it is combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Olaparib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Olaparib.Experimental
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Olaparib.Approved
AgmatineThe metabolism of Agmatine can be decreased when combined with Olaparib.Experimental, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Olaparib.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Olaparib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Olaparib.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Olaparib.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Olaparib.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Olaparib.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Olaparib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Olaparib.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Olaparib.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Olaparib.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Olaparib.Approved, Illicit, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Olaparib.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Olaparib.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Olaparib.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Olaparib.Approved
AmiodaroneThe serum concentration of Olaparib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Olaparib.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Olaparib.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Olaparib.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Olaparib.Approved, Investigational, Withdrawn
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Olaparib.Approved, Investigational
ApalutamideThe serum concentration of Olaparib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Olaparib.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Olaparib.Approved, Investigational
AprepitantThe serum concentration of Olaparib can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe metabolism of Aranidipine can be decreased when combined with Olaparib.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Olaparib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Olaparib.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Olaparib.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Olaparib.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Olaparib.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Olaparib.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Olaparib can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Olaparib can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Olaparib is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Olaparib.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Olaparib.Approved, Investigational
AxitinibThe metabolism of Axitinib can be decreased when combined with Olaparib.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Olaparib.Approved
AzelnidipineThe metabolism of Azelnidipine can be decreased when combined with Olaparib.Approved, Investigational
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Olaparib.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Olaparib.Investigational
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Olaparib.Approved, Investigational
BarnidipineThe metabolism of Barnidipine can be decreased when combined with Olaparib.Approved
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Olaparib is combined with Beclomethasone dipropionate.Approved, Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Olaparib.Approved
BencyclaneThe metabolism of Bencyclane can be decreased when combined with Olaparib.Experimental
BenidipineThe metabolism of Benidipine can be decreased when combined with Olaparib.Approved, Investigational
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Olaparib.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Olaparib.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Olaparib.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Olaparib.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Olaparib.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Olaparib.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Olaparib.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Olaparib.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Olaparib.Approved, Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Olaparib.Approved
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Olaparib.Approved, Investigational
BoceprevirThe serum concentration of Olaparib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Olaparib can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Olaparib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Olaparib.Approved
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Olaparib.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Olaparib.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Olaparib.Approved, Investigational
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Olaparib.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Olaparib.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Olaparib.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Olaparib.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Olaparib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Olaparib.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Olaparib.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Olaparib.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Olaparib.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Olaparib.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Olaparib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Olaparib.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Olaparib.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Olaparib.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Olaparib.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Olaparib.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Olaparib.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Olaparib.Approved, Investigational
CarbamazepineThe serum concentration of Olaparib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Olaparib.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be decreased when combined with Olaparib.Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Olaparib.Approved, Investigational
CaroverineThe metabolism of Caroverine can be decreased when combined with Olaparib.Experimental
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Olaparib.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Olaparib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Olaparib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Olaparib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Olaparib.Approved, Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Olaparib.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Olaparib.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Olaparib.Approved, Illicit, Investigational
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Olaparib.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Olaparib.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Olaparib.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Olaparib.Approved, Investigational
CilnidipineThe metabolism of Cilnidipine can be decreased when combined with Olaparib.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Olaparib.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Olaparib.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Olaparib.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Olaparib.Approved
ClarithromycinThe serum concentration of Olaparib can be increased when it is combined with Clarithromycin.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Olaparib.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Olaparib.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Olaparib.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Olaparib.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Olaparib.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Olaparib.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Olaparib.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Olaparib.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Olaparib.Approved
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Olaparib.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Olaparib.Approved, Illicit
ClotrimazoleThe serum concentration of Olaparib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Olaparib is combined with Clozapine.Approved
CobicistatThe serum concentration of Olaparib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Olaparib.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Olaparib.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Olaparib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Olaparib.Approved
ConivaptanThe serum concentration of Olaparib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Olaparib.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Olaparib.Approved, Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Olaparib.Approved, Investigational
CrizotinibThe serum concentration of Olaparib can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Olaparib can be increased when it is combined with Curcumin.Approved, Investigational
CyclandelateThe metabolism of Cyclandelate can be decreased when combined with Olaparib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Olaparib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Olaparib.Approved, Investigational
CyclosporineThe serum concentration of Olaparib can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Olaparib.Experimental
CytarabineThe metabolism of Cytarabine can be decreased when combined with Olaparib.Approved, Investigational
DabrafenibThe serum concentration of Olaparib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Olaparib.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Olaparib.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Olaparib.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Olaparib.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Olaparib.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Olaparib.Approved, Investigational
DarodipineThe metabolism of Darodipine can be decreased when combined with Olaparib.Experimental
DarunavirThe serum concentration of Olaparib can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Olaparib.Approved
DasatinibThe serum concentration of Olaparib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Olaparib.Approved
DeferasiroxThe serum concentration of Olaparib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Olaparib.Approved, Investigational
DelamanidThe metabolism of Delamanid can be decreased when combined with Olaparib.Approved, Investigational
DelavirdineThe serum concentration of Olaparib can be increased when it is combined with Delavirdine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Olaparib.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Olaparib.Approved, Investigational
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Olaparib.Approved, Investigational
DexamethasoneThe serum concentration of Olaparib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Olaparib.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Olaparib.Approved, Investigational
DexniguldipineThe metabolism of Dexniguldipine can be decreased when combined with Olaparib.Experimental
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Olaparib.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Olaparib.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe metabolism of Dexverapamil can be decreased when combined with Olaparib.Experimental
DiazepamThe metabolism of Diazepam can be decreased when combined with Olaparib.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Olaparib.Approved, Vet Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Olaparib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Olaparib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Olaparib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Olaparib.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Olaparib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Olaparib.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Olaparib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Olaparib.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Olaparib.Experimental
DihydroergotamineThe serum concentration of Olaparib can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Olaparib can be increased when it is combined with Diltiazem.Approved, Investigational
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Olaparib.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Olaparib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Olaparib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Olaparib.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Olaparib.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Olaparib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Olaparib.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Olaparib.Approved
DotarizineThe metabolism of Dotarizine can be decreased when combined with Olaparib.Investigational
DoxepinThe metabolism of Doxepin can be decreased when combined with Olaparib.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Olaparib.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Olaparib.Approved, Investigational
DoxycyclineThe serum concentration of Olaparib can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Olaparib.Approved, Illicit
DronedaroneThe serum concentration of Olaparib can be increased when it is combined with Dronedarone.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Olaparib.Approved, Investigational
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Olaparib.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be decreased when combined with Olaparib.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Olaparib.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Olaparib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Olaparib.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Olaparib.Approved
EmopamilThe metabolism of Emopamil can be decreased when combined with Olaparib.Experimental
EnalaprilThe metabolism of Enalapril can be decreased when combined with Olaparib.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Olaparib.Approved, Investigational
EnzalutamideThe serum concentration of Olaparib can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe metabolism of Eperisone can be decreased when combined with Olaparib.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Olaparib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Olaparib.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Olaparib.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Olaparib.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Olaparib.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Olaparib.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Olaparib.Approved, Investigational
ErythromycinThe serum concentration of Olaparib can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Olaparib.Approved, Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Olaparib.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Olaparib.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Olaparib.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Olaparib.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Olaparib.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Olaparib.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Olaparib.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Olaparib.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Olaparib.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Olaparib.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Olaparib.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Olaparib.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Olaparib.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Olaparib.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Olaparib.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Olaparib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Olaparib.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Olaparib.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Olaparib.Approved, Investigational
FelbamateThe metabolism of Felbamate can be decreased when combined with Olaparib.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Olaparib.Approved, Investigational
FendilineThe metabolism of Fendiline can be decreased when combined with Olaparib.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Olaparib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Olaparib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Olaparib.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Olaparib.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Olaparib.Approved, Investigational
Fish oilThe metabolism of Fish oil can be decreased when combined with Olaparib.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Olaparib is combined with Flibanserin.Approved, Investigational
FluconazoleThe serum concentration of Olaparib can be increased when it is combined with Fluconazole.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Olaparib.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Olaparib.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Olaparib.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Olaparib.Approved, Investigational
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Olaparib.Approved, Vet Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Olaparib.Approved, Illicit, Investigational
FluspirileneThe metabolism of Fluspirilene can be decreased when combined with Olaparib.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Olaparib.Approved, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Olaparib.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Olaparib is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Olaparib.Approved
FluvoxamineThe serum concentration of Olaparib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Olaparib can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Olaparib can be increased when it is combined with Fosaprepitant.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Olaparib.Approved
FosphenytoinThe serum concentration of Olaparib can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Olaparib.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Olaparib.Approved, Investigational
Fusidic AcidThe serum concentration of Olaparib can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe metabolism of Gabapentin can be decreased when combined with Olaparib.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Olaparib.Approved
GallopamilThe metabolism of Gallopamil can be decreased when combined with Olaparib.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Olaparib.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Olaparib.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Olaparib.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Olaparib.Experimental
GlipizideThe metabolism of Glipizide can be decreased when combined with Olaparib.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Olaparib.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Olaparib.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Olaparib.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Olaparib.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Olaparib.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Olaparib.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Olaparib.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Olaparib.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Olaparib.Approved, Investigational
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Olaparib.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Olaparib.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Olaparib is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Olaparib is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Olaparib.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Olaparib.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Olaparib.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Olaparib.Approved, Investigational
IdelalisibThe serum concentration of Olaparib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Olaparib resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Olaparib.Approved
ImatinibThe serum concentration of Olaparib can be increased when it is combined with Imatinib.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Olaparib.Approved, Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Olaparib.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Olaparib.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Olaparib.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Olaparib.Approved
IndinavirThe serum concentration of Olaparib can be increased when it is combined with Indinavir.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Olaparib.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium can be decreased when combined with Olaparib.Approved
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Olaparib.Approved, Investigational
IsavuconazoleThe serum concentration of Olaparib can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Olaparib can be increased when it is combined with Isavuconazonium.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Olaparib.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Olaparib.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Olaparib.Approved, Investigational
ItraconazoleThe serum concentration of Olaparib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Olaparib.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Olaparib.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Olaparib.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Olaparib.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Olaparib.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Olaparib.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Olaparib.Approved, Investigational
KetoconazoleThe serum concentration of Olaparib can be increased when it is combined with Ketoconazole.Approved, Investigational
LacidipineThe metabolism of Lacidipine can be decreased when combined with Olaparib.Approved, Investigational
LamotrigineThe metabolism of Lamotrigine can be decreased when combined with Olaparib.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Olaparib.Experimental
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Olaparib.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Olaparib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Olaparib.Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Olaparib.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Olaparib.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Olaparib.Approved, Investigational
LevetiracetamThe metabolism of Levetiracetam can be decreased when combined with Olaparib.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Olaparib.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Olaparib.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Olaparib.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Olaparib.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Olaparib.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Olaparib.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Olaparib.Approved, Vet Approved
LidoflazineThe metabolism of Lidoflazine can be decreased when combined with Olaparib.Experimental
LipegfilgrastimOlaparib may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Olaparib.Approved, Investigational
LomerizineThe metabolism of Lomerizine can be decreased when combined with Olaparib.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Olaparib.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Olaparib.Approved
LopinavirThe serum concentration of Olaparib can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Olaparib.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Olaparib.Approved
LorpiprazoleThe serum concentration of Olaparib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Olaparib.Approved
LovastatinThe serum concentration of Olaparib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Olaparib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Olaparib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Olaparib.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Olaparib.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Olaparib.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Olaparib.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Olaparib.Approved
Magnesium sulfateThe metabolism of Magnesium sulfate can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Manidipine can be decreased when combined with Olaparib.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Olaparib.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Olaparib.Approved, Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Olaparib.Experimental, Investigational
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Olaparib.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Olaparib.Approved, Investigational
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Olaparib.Approved, Vet Approved
MentholThe metabolism of Menthol can be decreased when combined with Olaparib.Approved
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Olaparib.Approved, Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Olaparib.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Olaparib.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Olaparib.Illicit, Withdrawn
MethimazoleThe risk or severity of adverse effects can be increased when Methimazole is combined with Olaparib.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Olaparib.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Olaparib.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Olaparib.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Olaparib.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Olaparib.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Olaparib.Experimental
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Olaparib.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Olaparib.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Olaparib.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Olaparib.Approved, Investigational
MibefradilThe serum concentration of Olaparib can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Olaparib can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Olaparib.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Olaparib.Approved
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Olaparib.Approved, Investigational
MifepristoneThe serum concentration of Olaparib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Olaparib.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Olaparib.Approved
MitotaneThe serum concentration of Olaparib can be decreased when it is combined with Mitotane.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Olaparib.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Olaparib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Olaparib.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Olaparib.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Olaparib.Approved, Investigational
NaftopidilThe metabolism of Naftopidil can be decreased when combined with Olaparib.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Olaparib.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Olaparib.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Olaparib.Approved, Investigational
NefazodoneThe serum concentration of Olaparib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Olaparib can be increased when it is combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Olaparib.Approved, Investigational
NetupitantThe serum concentration of Olaparib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Olaparib can be increased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Olaparib can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Olaparib.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Olaparib.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Olaparib.Approved
NiguldipineThe metabolism of Niguldipine can be decreased when combined with Olaparib.Experimental
NilotinibThe serum concentration of Olaparib can be increased when it is combined with Nilotinib.Approved, Investigational
NiludipineThe metabolism of Niludipine can be decreased when combined with Olaparib.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Olaparib.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Olaparib.Approved, Investigational
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Olaparib.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Olaparib.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Olaparib.Approved, Investigational
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Olaparib.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Olaparib.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Olaparib.Approved
NylidrinThe metabolism of Nylidrin can be decreased when combined with Olaparib.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Olaparib.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Olaparib.Experimental, Investigational
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Olaparib.Approved
OpiumThe metabolism of Opium can be decreased when combined with Olaparib.Approved, Illicit
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Olaparib.Approved
OsimertinibThe serum concentration of Olaparib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Olaparib.Approved, Investigational
OtiloniumThe metabolism of Otilonium can be decreased when combined with Olaparib.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Olaparib.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Olaparib.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Olaparib.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Olaparib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Olaparib.Approved, Vet Approved
PalbociclibThe serum concentration of Olaparib can be increased when it is combined with Palbociclib.Approved, Investigational
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Olaparib.Approved, Investigational
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Olaparib.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Olaparib.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Olaparib.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Olaparib.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Olaparib.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Olaparib.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Olaparib.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Olaparib.Approved
PenfluridolThe metabolism of Penfluridol can be decreased when combined with Olaparib.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Olaparib.Approved, Investigational
PentobarbitalThe serum concentration of Olaparib can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Olaparib.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Olaparib.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Olaparib.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Olaparib.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Olaparib.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Olaparib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Olaparib.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Olaparib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Olaparib.Withdrawn
PhenobarbitalThe serum concentration of Olaparib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Olaparib.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Olaparib.Approved, Investigational
PhenytoinThe serum concentration of Olaparib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Olaparib.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Olaparib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Olaparib.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Olaparib.Approved
PinaveriumThe metabolism of Pinaverium can be decreased when combined with Olaparib.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Olaparib.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Olaparib.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Olaparib.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Olaparib.Approved
PitolisantThe serum concentration of Olaparib can be decreased when it is combined with Pitolisant.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Olaparib.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Olaparib.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Olaparib.Approved, Investigational
PosaconazoleThe serum concentration of Olaparib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Olaparib.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Olaparib.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Olaparib.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Olaparib.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Olaparib.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Olaparib.Approved, Vet Approved
PregabalinThe metabolism of Pregabalin can be decreased when combined with Olaparib.Approved, Illicit, Investigational
PrenylamineThe metabolism of Prenylamine can be decreased when combined with Olaparib.Withdrawn
PrimaquineThe metabolism of Primaquine can be decreased when combined with Olaparib.Approved
PrimidoneThe serum concentration of Olaparib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Olaparib.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Olaparib.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Olaparib.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Olaparib.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Olaparib.Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Olaparib.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Olaparib.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Olaparib.Experimental
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Olaparib.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Olaparib.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Olaparib.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Olaparib.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Olaparib.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Olaparib.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Olaparib.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Olaparib.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Olaparib.Approved, Investigational
RanolazineThe serum concentration of Olaparib can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Olaparib.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Olaparib.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Olaparib.Approved, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Olaparib.Approved
RifabutinThe serum concentration of Olaparib can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Olaparib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Olaparib can be decreased when it is combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Olaparib.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Olaparib.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Olaparib.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Olaparib.Approved, Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Olaparib.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Olaparib.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Olaparib.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Olaparib.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Olaparib.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Olaparib.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Olaparib.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Olaparib.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Olaparib.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Olaparib can be increased when it is combined with Rucaparib.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Olaparib.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Olaparib.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Olaparib.Approved, Investigational
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Olaparib.Approved
SaquinavirThe serum concentration of Olaparib can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Olaparib can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Olaparib.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
SeletracetamThe metabolism of Seletracetam can be decreased when combined with Olaparib.Investigational
SelexipagThe metabolism of Selexipag can be decreased when combined with Olaparib.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Olaparib.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Olaparib.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Olaparib.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Olaparib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Olaparib can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe metabolism of Silodosin can be decreased when combined with Olaparib.Approved
SiltuximabThe serum concentration of Olaparib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Olaparib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Olaparib.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Olaparib.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Olaparib.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Olaparib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Olaparib.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Olaparib.Approved, Investigational
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Olaparib.Approved
St. John's WortThe serum concentration of Olaparib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Olaparib can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Olaparib.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Olaparib.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Olaparib is combined with Sulfasalazine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Olaparib.Approved
SulfisoxazoleThe serum concentration of Olaparib can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Olaparib.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Olaparib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Olaparib.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Olaparib.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Olaparib.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Olaparib.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Olaparib.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Olaparib.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Olaparib.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Olaparib.Experimental
TelaprevirThe serum concentration of Olaparib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Olaparib can be increased when it is combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Olaparib.Approved, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Olaparib.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Olaparib.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Olaparib.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Olaparib.Experimental
TerodilineThe metabolism of Terodiline can be decreased when combined with Olaparib.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Olaparib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Olaparib.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Olaparib.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Olaparib.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Olaparib.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Olaparib.Approved, Vet Approved
TetrahydropalmatineThe metabolism of Tetrahydropalmatine can be decreased when combined with Olaparib.Investigational
TetrandrineThe risk or severity of adverse effects can be increased when Olaparib is combined with Tetrandrine.Experimental
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Olaparib.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Olaparib.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Olaparib.Approved, Investigational
TiagabineThe metabolism of Tiagabine can be decreased when combined with Olaparib.Approved, Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Olaparib.Approved
TiclopidineThe serum concentration of Olaparib can be increased when it is combined with Ticlopidine.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Olaparib.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Olaparib.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Olaparib.Approved, Investigational
TocilizumabThe serum concentration of Olaparib can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Olaparib.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Olaparib.Approved, Investigational
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Olaparib.Approved, Investigational
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be decreased when combined with Olaparib.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Olaparib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Olaparib.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Olaparib.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Olaparib.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Olaparib.Approved, Investigational
TranilastThe metabolism of Tranilast can be decreased when combined with Olaparib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Olaparib.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Olaparib.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Olaparib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Olaparib.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Olaparib.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Olaparib.Approved, Investigational
TrimebutineThe metabolism of Trimebutine can be decreased when combined with Olaparib.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Olaparib.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Olaparib.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Olaparib.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Olaparib.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Olaparib.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Olaparib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Olaparib.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Olaparib.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Olaparib.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Olaparib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Olaparib.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Olaparib.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Olaparib.Approved, Investigational
VemurafenibThe serum concentration of Olaparib can be decreased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Olaparib.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Olaparib.Approved
VerapamilThe serum concentration of Olaparib can be increased when it is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Olaparib.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Olaparib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Olaparib.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Olaparib.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Olaparib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Olaparib.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Olaparib.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Olaparib.Approved, Investigational
VinpocetineThe metabolism of Vinpocetine can be decreased when combined with Olaparib.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Olaparib.Approved, Investigational
VoriconazoleThe serum concentration of Olaparib can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Olaparib.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Olaparib.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Olaparib.Approved
WIN 55212-2The metabolism of WIN 55212-2 can be decreased when combined with Olaparib.Experimental
YohimbineThe metabolism of Yohimbine can be decreased when combined with Olaparib.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Olaparib.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Olaparib.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Olaparib.Approved, Illicit, Investigational
ZiconotideThe metabolism of Ziconotide can be decreased when combined with Olaparib.Approved
ZidovudineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Olaparib.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Olaparib can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Olaparib.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Olaparib.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Olaparib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Olaparib.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Olaparib.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Olaparib.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM: 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91. doi: 10.1021/jm8001263. Epub 2008 Sep 19. Pubmed

General References
  1. Frampton JE: Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs. 2015 Apr;29(2):143-50. doi: 10.1007/s40259-015-0125-6. [PubMed:25899311]
  2. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM: 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91. doi: 10.1021/jm8001263. Epub 2008 Sep 19. [PubMed:18800822]
  3. Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, Smith GC, Martin NM, O'Connor M, Clarke AR: Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 2009 May 1;69(9):3850-5. doi: 10.1158/0008-5472.CAN-08-2388. Epub 2009 Apr 21. [PubMed:19383921]
  4. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J: High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29. [PubMed:18971340]
External Links
KEGG Drug
D09730
ChemSpider
23343272
BindingDB
27566
ChEBI
83766
ChEMBL
CHEMBL521686
HET
09L
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Olaparib
ATC Codes
L01XX46 — Olaparib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
3u9y / 4tkg / 4tvj / 5ds3
FDA label
Download (297 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
0RecruitingNot AvailableEndometrial Carcinoma1
0RecruitingBasic ScienceCancer of the Ovary1
0RecruitingTreatmentCancer of the Ovary1
1Active Not RecruitingBasic ScienceTumors, Solid2
1Active Not RecruitingOtherTumors, Solid2
1Active Not RecruitingTreatmentAdvanced Ovarian Cancer / Carboplatin / Paclitaxel / Triple Negative Metastatic Breast Cancer1
1Active Not RecruitingTreatmentAdvanced Solid Tumors1
1Active Not RecruitingTreatmentBRCA1 Protein / BRCA2 Protein / Neoplasms, Ovarian1
1Active Not RecruitingTreatmentBone Tumors / Soft Tissue Sarcoma (STS)1
1Active Not RecruitingTreatmentCancer of the Ovary / Cancer, Breast1
1Active Not RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1Active Not RecruitingTreatmentTumors, Solid1
1CompletedTreatmentAdvanced Solid Malignancies1
1CompletedTreatmentAdvanced Solid Malignancies / Cancers1
1CompletedTreatmentAdvanced Solid Tumours1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentCancer of the Ovary / Cancer, Breast / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Triple Negative Breast Cancer (TNBC)1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentMalignant Solid Tumours1
1CompletedTreatmentMelanoma Neoplasms1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNeoplasms Metastasis2
1CompletedTreatmentNeoplasms, Pancreatic1
1Not Yet RecruitingTreatmentMalignant Lymphomas1
1Not Yet RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1RecruitingOtherProstate Cancer1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentAdvanced Solid Tumours1
1RecruitingTreatmentAnatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Prognostic Stage IV Breast Cancer AJCC v8 / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentBreast Neoplasm Malignant Female / Breast Neoplasms, Triple-Negative / Radiotherapy Side Effect1
1RecruitingTreatmentCancer of the Ovary / Cancer, Advanced / Cancer, Breast1
1RecruitingTreatmentCarcinoma of the Oesophagus1
1RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / High Grade Fallopian Tube Serous Adenocarcinoma / High Grade Ovarian Serous Adenocarcinoma / Metastatic Malignant Solid Neoplasm / Metastatic Solid Neoplasm / Primary Peritoneal High Grade Serous Adenocarcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Triple-Negative Breast Carcinoma / Unresectable Malignant Solid Neoplasm / Unresectable Solid Neoplasm1
1RecruitingTreatmentEwing's Sarcoma (ES)1
1RecruitingTreatmentHead and Neck Carcinoma1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1RecruitingTreatmentInflammatory Breast Carcinoma / Locally Advanced Malignant Neoplasm / Triple-Negative Invasive Breast Carcinoma1
1RecruitingTreatmentLaryngeal Cancer Stage II / Laryngeal Cancer Stage III / Neoplasms, Head and Neck / Squamous Cell Carcinoma (SCC)1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentMalignant Neoplasm of Breast / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands1
1RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer / Prostatic Neoplasms1
1RecruitingTreatmentMuscle Invasive Bladder Cancer1
1RecruitingTreatmentOvarian, Breast, and Second-Line Small Cell Lung Cancer / Refractory Solid Tumours / Relapsed Small Cell Lung Cancer (SCLC)1
1RecruitingTreatmentSoft-Tissue Sarcoma1
1RecruitingTreatmentTumors, Solid1
1Unknown StatusTreatmentCancer, Advanced1
1WithdrawnTreatmentSquamous Cell Carcinoma (SCC)1
1, 2Active Not RecruitingTreatmentCancer, Breast / Malignant Female Reproductive System Neoplasm1
1, 2Active Not RecruitingTreatmentDeleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Estrogen Receptor Negative / HER2/Neu Negative / Ovarian Endometrioid Adenocarcinoma / Ovarian Serous Adenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Serous Surface Papillary Adenocarcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Triple-Negative Breast Carcinoma1
1, 2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2Active Not RecruitingTreatmentStage III Ovarian Cancer / Stage IV Ovarian Cancer / Uterine Cancers1
1, 2Not Yet RecruitingTreatmentAdenocarcinoma, Prostate / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Metastatic Malignant Neoplasm in the Bone / PSA Progression1
1, 2Not Yet RecruitingTreatmentMalignant Lymphomas / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2Not Yet RecruitingTreatmentRecurrent Endometrial Cancer1
1, 2RecruitingDiagnosticOral Squamous Cell Carcinoma (OSCC)1
1, 2RecruitingTreatmentAbdominal wall neoplasm / Cancer of the Ovary / Fallopian Tube Cancer1
1, 2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Metastatic Malignant Neoplasm in the Lymph Nodes / Recurrent Gastric Carcinoma / Stage IV Gastric Cancer AJCC v71
1, 2RecruitingTreatmentAdvanced Solid Tumors / Cancer of the Ovary / Cancer, Advanced / Cancer, Breast / Endometrial Cancers1
1, 2RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Ovarian Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
1, 2RecruitingTreatmentBreast / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Stomach / Ovarian1
1, 2RecruitingTreatmentCancer of the Ovary / Cancer, Breast / Colorectal Cancers / Lung Cancers / Prostate Cancer / Triple Negative Breast Cancer (TNBC)1
1, 2RecruitingTreatmentChildren, Adolescents and Young Adults With Refractory or Recurrent Malignancies1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Lung Cancers / Neoplasms, Lung / Small Cell Lung Carcinoma / Tumors, Solid1
1, 2RecruitingTreatmentMalignant Gliomas / PARP Inhibitor / Radiotherapy1
1, 2RecruitingTreatmentNeoplasms, Breast1
1, 2RecruitingTreatmentPrimary Peritoneal Carcinoma1
1, 2WithdrawnTreatmentCancer of the Breast1
2Active Not RecruitingTreatmentAdvanced Tumours / Breast / Ovarian / Pancreatic / Prostate1
2Active Not RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / High Grade Ovarian Serous Adenocarcinoma / Ovarian Endometrioid Tumor / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2Active Not RecruitingTreatmentCancer of the Ovary2
2Active Not RecruitingTreatmentCancer, Breast / Ovarian Carcinoma1
2Active Not RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
2Active Not RecruitingTreatmentNeoplasms, Breast1
2Active Not RecruitingTreatmentNeoplasms, Ovarian1
2CompletedTreatmentCancer of the Ovary3
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentEwing's Sarcoma (ES)1
2CompletedTreatmentNeoplasms, Ovarian1
2Not Yet RecruitingTreatmentATM Biallelic Inactivation / ATM Gene Mutation / ATM Monoallelic Inactivation / BRCA1 Biallelic Inactivation / BRCA1 Gene Mutation / BRCA2 Biallelic Inactivation / Brca2 Gene Mutation / FANCA Biallelic Inactivation / Homologous Recombination Deficiency / PALB2 Biallelic Inactivation / PALB2 Gene Mutation / Prostate Adenocarcinoma Without Evidence of Neuroendocrine Differentiation / Stage I Prostate Cancer AJCC v8 / Stage II Prostate Cancer AJCC v8 / Stage IIA Prostate Cancer AJCC v8 / Stage IIB Prostate Cancer AJCC v8 / Stage IIC Prostate Cancer AJCC v81
2Not Yet RecruitingTreatmentAbnormal DNA Repair / ATM Gene Mutation / ATR Gene Mutation / BAP1 Gene Mutation / BARD1 Gene Mutation / BLM Gene Mutation / BRCA1 Gene Mutation / Brca2 Gene Mutation / BRIP1 Gene Mutation / CHEK1 Gene Mutation / CHEK2 Gene Mutation / FANCC Gene Mutation / FANCD2 Gene Mutation / FANCE Gene Mutation / FANCF Gene Mutation / MEN1 Gene Mutation / MLH1 Gene Mutation / MSH2 Gene Mutation / MSH6 Gene Mutation / MUTYH Gene Mutation / NPM1 Gene Mutation / PALB2 Gene Mutation / PMS2 Gene Mutation / POLD1 Gene Mutation / POLE Gene Mutation / PRKDC Gene Mutation / RAD50 Gene Mutation / RAD51 Gene Mutation / SMARCB1 Gene Mutation / Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 / Stage IV Bladder Urothelial Carcinoma AJCC v7 / STK11 Gene Mutation / Transitional Cell Carcinoma / Urothelial carcinoma ureter metastatic1
2Not Yet RecruitingTreatmentATM Gene Mutation / Breast Cancer Invasive Nos / BRIP1 Gene Mutation / CHEK2 Gene Mutation / Metastatic Breast Cancer (MBC) / NBN Gene Mutation / PALB2 Gene Mutation / RAD51 Gene Mutation / Somatic Mutation Breast Cancer (BRCA1) / Somatic Mutation Breast Cancer (BRCA2)1
2Not Yet RecruitingTreatmentAdenocarcinoma, Prostate / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / PSA Level Greater Than or Equal to One / PSA Progression1
2Not Yet RecruitingTreatmentAdvanced Gastric Cancer1
2Not Yet RecruitingTreatmentBladder Cancers1
2Not Yet RecruitingTreatmentCancers With DNA Repair-Deficiency1
2Not Yet RecruitingTreatmentInflammatory Breast Carcinoma1
2Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Not Yet RecruitingTreatmentMutant High Grade Glioma / Recurrent IDH / Recurrent IDH-mutant High Grade Glioma1
2Not Yet RecruitingTreatmentOvarian Epithelial Cancer1
2Not Yet RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Primary Peritoneal Carcinoma / Refractory Ovarian Carcinoma1
2RecruitingScreeningAdvanced Malignant Solid Neoplasm / Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma / Childhood Langerhans Cell Histiocytosis / Histiocytic Sarcoma (HS) / Juvenile Xanthogranuloma / Langerhans Cell Histiocytosis (LCH) / Malignant Gliomas / Malignant Lymphomas / Recurrent Central Nervous System Neoplasm / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma / Recurrent Gliomas / Recurrent Hepatoblastoma / Recurrent Langerhans Cell Histiocytosis / Recurrent Malignant Solid Neoplasm / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Peripheral Primitive Neuroectodermal Tumor / Refractory Central Nervous System Neoplasm / Refractory Childhood Malignant Germ Cell Tumor / Refractory Langerhans cell histiocytosis / Refractory Malignant Solid Neoplasm / Refractory Neuroblastoma / Rhabdoid Tumors / Stage III Childhood Non-Hodgkin Lymphoma / Stage III Osteosarcoma / Stage III Osteosarcoma AJCC v7 / Stage III Soft Tissue Sarcoma / Stage III Soft Tissue Sarcoma AJCC v7 / Stage IV Childhood Non-Hodgkin Lymphoma / Stage IV Osteosarcoma / Stage IV Osteosarcoma AJCC v7 / Stage IV Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma AJCC v7 / Stage IVA Osteosarcoma / Stage IVA Osteosarcoma AJCC v7 / Stage IVB Osteosarcoma / Stage IVB Osteosarcoma AJCC v7 / Wilms' tumor1
2RecruitingTreatmentAbnormal DNA Repair / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Cancer Metastatic Castration-Resistant / Stage IV Prostate Cancer1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / BRCA1 wt Allele / BRCA2 wt Allele / Estrogen Receptor Negative / HER2/Neu Negative / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Small Cell Lung Carcinoma / Stage III Breast Cancer / Stage III Breast Cancer AJCC V7 / Stage III Non-Small Cell Lung Cancer / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage III Small Cell Lung Carcinoma / Stage III Small Cell Lung Carcinoma AJCC v7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Small Cell Lung Carcinoma / Stage IIIA Small Cell Lung Carcinoma AJCC v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Small Cell Lung Carcinoma / Stage IIIB Small Cell Lung Carcinoma AJCC v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v7 / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IV Small Cell Lung Carcinoma / Stage IV Small Cell Lung Carcinoma AJCC v7 / Stage IVA Pancreatic Cancer / Stage IVB Pancreatic Cancer / Triple-Negative Breast Carcinoma / Unresectable Pancreatic Carcinoma1
2RecruitingTreatmentAdenocarcinoma of the Prostate1
2RecruitingTreatmentAdvanced Breast Cancer1
2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma / Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma / Deleterious ATM Gene Mutation / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Deleterious RAD51C Gene Mutation / Deleterious RAD51D Gene Mutation / Histiocytosis / Low Grade Glioma (LGG) / Malignant Gliomas / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Gliomas / Recurrent Hepatoblastoma / Recurrent Langerhans Cell Histiocytosis / Recurrent Malignant Solid Neoplasm / Recurrent Medulloblastoma / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Refractory Central Nervous System Neoplasm / Refractory Langerhans cell histiocytosis / Refractory Malignant Solid Neoplasm / Refractory Neuroblastoma / Refractory Non-Hodgkin's lymphoma / Rhabdoid Tumors / Stage III Childhood Non-Hodgkin Lymphoma / Stage IV Childhood Non-Hodgkin Lymphoma / Wilms' tumor1
2RecruitingTreatmentAdvanced Ovarian Cancer1
2RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)2
2RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage III Breast Cancer AJCC V7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v7 / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v7 / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentCancer of Unknown Primary Site1
2RecruitingTreatmentCancer of the Ovary2
2RecruitingTreatmentCancer of the Ovary / Debulking Surgical Procedures / Fallopian Tube Cancer / Neoadjuvant Treatment1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCancers / Neoplasia / Neoplasms / Tumors1
2RecruitingTreatmentCarcinosarcoma / Neoplasms, Endometrial1
2RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation / Prostate Carcinoma Metastatic in the Bone / Prostate Small Cell Carcinoma / PSA Progression / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma AJCC v71
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2RecruitingTreatmentMalignant Neoplasm of Pancreas2
2RecruitingTreatmentMesothelioma1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
2RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
2RecruitingTreatmentMetastatic Urothelial Cancer1
2RecruitingTreatmentNeoplasms, Germ Cell and Embryonal1
2RecruitingTreatmentNeoplasms, Ovarian1
2RecruitingTreatmentPlatinum Refractory Extensive-Stage Small Cell Lung Carcinoma1
2RecruitingTreatmentProstate1
2RecruitingTreatmentProstate Cancer / Prostate Cancer Aggressiveness1
2RecruitingTreatmentRare Tumor / Refractory Tumors1
2RecruitingTreatmentRecurrent Glioblastoma1
2RecruitingTreatmentRecurrent Platinum Resistant Ovarian Cancer1
2RecruitingTreatmentRelapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity1
2RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingTreatmentUrinary Bladder Neoplasms1
2SuspendedTreatmentAdvanced Malignant Solid Neoplasm / Glioblastomas / Grade II Glioma / IDH1 Gene Mutation / IDH2 Gene Mutation / Recurrent Cholangiocarcinoma / Recurrent Gliomas / Recurrent Malignant Solid Neoplasm / WHO Grade II Glioma / WHO Grade III Glioma1
2SuspendedTreatmentExtensive Stage Small Cell Lung Carcinoma / Small Cell Lung Carcinoma1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2WithdrawnTreatmentCancer of the Ovary / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
2, 3RecruitingTreatmentCancer, Breast1
2, 3SuspendedTreatmentDeleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentAdvanced Ovarian Cancer / BRCA Mutation / Complete Response / FIGO Stage III-IV / First Line Platinum Chemotherapy / Newly Diagnosed / Partial Response1
3Active Not RecruitingTreatmentBRCA 1 Gene Mutation / BRCA 2 Gene Mutation / Breast Cancer Metastatic1
3Active Not RecruitingTreatmentBRCA Mutated / Following Complete or Partial Response to Platinum Based Chemotherapy / Platinum Sensitive / Recurrent Ovarian Cancer1
3Active Not RecruitingTreatmentBRCA Rearrangement / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Endometrial Undifferentiated Carcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Tumor / Ovarian Seromucinous Carcinoma / Ovarian Serous Tumor / Ovarian Transitional Cell Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentRelapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity1
3Not Yet RecruitingTreatmentCancer of the Ovary1
3RecruitingPreventionCancer, Breast1
3RecruitingTreatmentCancer of the Ovary1
3RecruitingTreatmentFollowing Complete or Partial Response to Platinum Based Chemotherapy / Platinum Sensitive / Recurrent Ovarian Cancer1
3RecruitingTreatmentGermline BRCA1/2 Mutations and / Metastatic Adenocarcinoma of the Pancreas1
3RecruitingTreatmentGermline BRCA1/2 Mutations / HER2-ve Metastatic Breast Cancer1
3RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
3RecruitingTreatmentNon-Germline BRCA Mutated Ovarian Cancer1
3RecruitingTreatmentOvarian Epithelial Cancer1
3WithdrawnTreatmentPlatinum Sensitive Relapsed Ovarian Cancer1
4RecruitingOtherBRCA or HRR+ Mutated Ovarian Cancer Patients / BRCAm Ovarian Cancer1
Not AvailableApproved for MarketingNot AvailableCancer of the Ovary1
Not AvailableNo Longer AvailableNot AvailablePSR Ovarian Cancer With a BRCA Mutation1
Not AvailableRecruitingTreatmentCancer of the Ovary1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral50 mg
CapsuleOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8859562No2011-08-042031-08-04Us
US8912187No2004-03-122024-03-12Us
US8143241No2007-08-122027-08-12Us
US7449464No2004-10-112024-10-11Us
US8247416No2008-09-242028-09-24Us
US7151102No2002-04-292022-04-29Us
US7981889No2004-10-112024-10-11Us
US8475842No2009-12-312029-12-31Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.119 mg/mLALOGPS
logP2.68ALOGPS
logP2.32ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)8.75ChemAxon
pKa (Strongest Basic)2.24ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.63 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity118.63 m3·mol-1ChemAxon
Polarizability44.03 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phthalazinones. These are compounds containing a phthalazine bearing a ketone group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Phthalazinones
Alternative Parents
2-halobenzoic acids and derivatives / Benzamides / Benzoyl derivatives / Fluorobenzenes / Pyridazines and derivatives / Piperazines / Aryl fluorides / Cyclopropanecarboxylic acids and derivatives / Vinylogous halides / Tertiary carboxylic acid amides
show 8 more
Substituents
Phthalazinone / 2-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzoic acid or derivatives / Benzamide / Benzoyl / Fluorobenzene / Halobenzene / Monocyclic benzene moiety / Benzenoid
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cyclopropanes, monofluorobenzenes, phthalazines, N-acylpiperazine (CHEBI:83766)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This ...
Gene Name
PARP1
Uniprot ID
P09874
Uniprot Name
Poly [ADP-ribose] polymerase 1
Molecular Weight
113082.945 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nad+ adp-ribosyltransferase activity
Specific Function
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This ...
Gene Name
PARP2
Uniprot ID
Q9UGN5
Uniprot Name
Poly [ADP-ribose] polymerase 2
Molecular Weight
66205.31 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nad+ adp-ribosyltransferase activity
Specific Function
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This ...
Gene Name
PARP3
Uniprot ID
Q9Y6F1
Uniprot Name
Poly [ADP-ribose] polymerase 3
Molecular Weight
60069.7 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C: Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13. [PubMed:25981132]

Drug created on May 14, 2015 14:38 / Updated on August 15, 2018 09:56